Hypertension management in patients with cardiovascular comorbidities
Résumé
Abstract Arterial hypertension is a leading cause of death globally. Due to ageing, the rising incidence of obesity, and socioeconomic and environmental changes, its incidence increases worldwide. Hypertension commonly coexists with Type 2 diabetes, obesity, dyslipidaemia, sedentary lifestyle, and smoking leading to risk amplification. Blood pressure lowering by lifestyle modifications and antihypertensive drugs reduce cardiovascular (CV) morbidity and mortality. Guidelines recommend dual- and triple-combination therapies using renin–angiotensin system blockers, calcium channel blockers, and/or a diuretic. Comorbidities often complicate management. New drugs such as angiotensin receptor-neprilysin inhibitors, sodium–glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists improve CV and renal outcomes. Catheter-based renal denervation could offer an alternative treatment option in comorbid hypertension associated with increased sympathetic nerve activity. This review summarises the latest clinical evidence for managing hypertension with CV comorbidities.
Mots clés
Hypertension Cardiovascular comorbidities Heart failure Chronic kidney disease Atrial fibrillation Chronic obstructive pulmonary disease Obesity Diabetes mellitus Stroke Transient ischemic attack Aortic valve stenosis
Hypertension
Cardiovascular comorbidities
Heart failure
Chronic kidney disease
Atrial fibrillation
Chronic obstructive pulmonary disease
Obesity
Diabetes mellitus
Stroke
Transient ischemic attack
Aortic valve stenosis
Domaines
Sciences du Vivant [q-bio]Origine | Fichiers éditeurs autorisés sur une archive ouverte |
---|---|
Licence |